Prime Medicine (PRME) Shares Outstanding (Weighted Average) (2021 - 2026)

Prime Medicine has reported Shares Outstanding (Weighted Average) for 6 years, with the latest figure at $177.1 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 35.31% year-over-year to $177.1 million; the trailing twelve-month figure through Mar 2026 stood at $177.1 million (up 35.31% YoY), and the FY2025 full-year result was $148.8 million, up 25.43% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $177.1 million, up from $148.8 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $177.1 million in Q1 2026, with the low at $19.1 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $97.5 million across 5 years, with a median of $104.5 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) soared 367.52% — and 2025, when it climbed 15.52%.
• Prime Medicine's Shares Outstanding (Weighted Average) stood at $33.9 million in 2022, then soared by 168.42% to $91.0 million in 2023, then surged by 30.37% to $118.6 million in 2024, then grew by 25.43% to $148.8 million in 2025, then grew by 19.05% to $177.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $177.1 million (Q1 2026), $148.8 million (Q4 2025), and $160.5 million (Q3 2025), per Business Quant data.